Dimitry Nuyten
Direttore Tecnico/Scientifico/R&S presso ARCUS BIOSCIENCES, INC.
Patrimonio netto: 208 267 $ in data 31/05/2024
Profilo
Dimitry S.
A.
Nuyten is currently the Chief Medical Officer at Arcus Biosciences, Inc. He previously worked as the Group Medical Director at Bristol Myers Squibb Co. from 2008 to 2013, and as the Vice President at Pfizer Inc. from 2013 to 2019.
In 2021, he was the Chief Medical Officer & Senior Vice President at Nektar Therapeutics.
He also served as the Chief Medical Officer at Aduro BioTech, Inc. Dr. Nuyten holds a doctorate degree from both the University of Amsterdam and the University of Groningen.
Partecipazioni note in società pubbliche
| Società | Data | Numero di azioni | Valorizzazione | Data di valutazione |
|---|---|---|---|---|
ARCUS BIOSCIENCES, INC.
0.02% | 01/03/2024 | 13 820 ( 0.02% ) | 208 267 $ | 31/05/2024 |
Posizioni attive di Dimitry Nuyten
| Società | Posizione | Inizio |
|---|---|---|
| ARCUS BIOSCIENCES, INC. | Direttore Tecnico/Scientifico/R&S | 01/08/2022 |
Precedenti posizioni note di Dimitry Nuyten
| Società | Posizione | Fine |
|---|---|---|
| NEKTAR THERAPEUTICS | Direttore Tecnico/Scientifico/R&S | 01/04/2022 |
| PFIZER, INC. | Corporate Officer/Principal | 01/03/2019 |
| BRISTOL-MYERS SQUIBB COMPANY | Direttore Tecnico/Scientifico/R&S | 01/06/2013 |
| CHINOOK THERAPEUTICS, INC. | Direttore Tecnico/Scientifico/R&S | - |
Formazione di Dimitry Nuyten
| University of Groningen | Doctorate Degree |
| University of Amsterdam | Doctorate Degree |
Esperienze
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Relazioni
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
| Società quotate in Borsa | 4 |
|---|---|
| PFIZER, INC. | Health Technology |
| BRISTOL-MYERS SQUIBB COMPANY | Health Technology |
| NEKTAR THERAPEUTICS | Health Technology |
| ARCUS BIOSCIENCES, INC. | Health Technology |
| Aziende private | 1 |
|---|---|
Aduro BioTech, Inc.
 Aduro BioTech, Inc. Pharmaceuticals: MajorHealth Technology Aduro BioTech, Inc. is a clinical-stage immunotherapy company, which engages in the discovery, development, and commercialization of therapies that transform the treatment of diseases, including cancer. Its technology platforms include STING Pathway Activator, B-select monoclonal antibody, and LADD, or Live, Attenuated, Double-Deleted Listeria monocytogenes. The company's platforms stimulate and/or regulate innate and adaptive immune responses, either as single agents or in combination with conventional therapies like chemotherapy and radiation as well as other novel immunotherapies. Aduro BioTech was founded in 2000 and is headquartered in Berkeley, CA. | Health Technology |
- Borsa valori
- Insiders
- Dimitry Nuyten
